Wednesday, 13 July 2011

First results from clinical trial of alemtuzumab

Source: The MS Trust
In a phase III clinical trial, alemtuzumab (Campath, Lemtrada) was better at preventing relapses than Rebif, but did not stop an increase in disability.  For more information click here.